Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02896595
Other study ID # HM20007902
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date January 31, 2019

Study information

Verified date January 2020
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In recent years it has been shown that catheter ablation of symptomatic atrial fibrillation (PAF) is superior to antiarrhythmic drug therapy with regards to effectiveness and clinical outcomes. Atrial fibrillation is the most common cardiac arrhythmia, with high rates of concomitant heart failure, stroke and mortality. During an ablation procedure, a patient can be managed with intravenous sedation or General Anesthesia (GA). Within this setting, General anesthesia is associated with improved procedure time and cure rate compared to sedation.

Airway management during GA can be achieved through a laryngeal mask airway (LMA) or an endotracheal tube (ETT). The use of LMA compared to ETT has been shown in different surgical populations to decrease procedure and recovery time, improve hemodynamic stability and reduce anesthetic requirements. It has also shown to decrease airway complications, and postoperative nausea/vomiting which are important factors that affect overall patient satisfaction.

Although general anesthesia in electrophysiology procedures is associated with a higher cure rate, there have been reports of increased airway trauma.Additionally, it is believed that volatile anesthetics may be associated with increased ventricular action potential duration as well as prolonged QT interval. The increased usage of opioids during general anesthesia is also thought to interfere with electrophysiology studies by affecting vagal tone.

At Virginia Commonwealth University (VCU) Health system, Anesthesiologists have been successfully using LMA (General Anesthesia) for ablation in PAF in eligible patients for over five years. The investigators plan to perform a retrospective review of all patients who underwent catheter ablation of PAF at Virginia Commonwealth University Health System from January 2014 - December 2015. The primary endpoint evaluated will be procedure time. Other data collected will include demographics, cardiac history, type of anesthesia, amount of intra-procedure opioids, time to discharge from post anesthesia care unit (PACU), total length of hospital stay, intra-procedure hemodynamics, intra-procedure ionotrope/chronotrope/pressor requirements. and atrial fibrillation recurrence at a 3 month follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 31, 2019
Est. primary completion date December 11, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Patients undergoing primary ablation for paroxysmal atrial fibrillation

- Able to obtain consent in English language

- BMI <35

Exclusion Criteria:

- Patients <18 years old

- Patients undergoing ablation for arrhythmias other than paroxysmal atrial fibrillation

- American Society of Anesthesiologist physical status of 4 or greater

- Patients undergoing repeat ablation

- BMI >35

- Pregnancy

- Prisoners

- Patients unable to give their own consent

- Patients having trans esophageal echo on the same day

- Patients unable to give consent in English language

- Patients will also be excluded if the attending anesthesiologist determines that they would not be suitable candidates for intubation with either method (ETT tube or LMA mask).

- Patients with severe gastroesophageal reflux disease

- Patients with high risk of aspiration

Study Design


Related Conditions & MeSH terms


Intervention

Device:
General Anesthesia with endotracheal tube
Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
General Anesthesia with laryngeal mask airway
Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure Time (Minutes) Will be measured as time from start of procedure to end of procedure, as recorded in minutes Up to 270 minutes
Secondary Fluoroscopy Time As measured and reported by electrophysiology and radiology notes, recorded in minutes Up to 270 minutes
Secondary Total Anesthesia Time Total anesthesia time as measured in minutes and recorded in the anesthesia record, from anesthesia start time to anesthesia stop time Up to 270 minutes
Secondary Time to Discharge From PACU time from arrival to PACU until discharge from anesthesia care Up to 7 days
Secondary Total Intra-procedure Opioids Measured in mcg of Fentanyl Up to 270 minutes
Secondary Anesthetic Requirements average end tidal volatile anesthetics Measured as intra operative anesthetic (MAC) Up to 270 minutes
Secondary Anesthetic Requirements average amount of intravenous anesthetics Up to 270 minutes
Secondary Intraoperative Hemodynamics heart rate (beats per minute) Up to 270 minutes
Secondary Intraoperative Hemodynamics mean arterial pressure Up to 270 minutes
Secondary Intraoperative Hemodynamics systolic blood pressure Up to 270 minutes
Secondary Intraoperative Hemodynamics diastolic blood pressure Up to 270 minutes
Secondary Intraprocedure Pressor/Ionotrope/Chronotrope Requirements total measured amounts of all pressors/ionotropes and chronotropes administered intraoperatively Up to 270 minutes
Secondary Electrophysiology Parameters duration of paroxysmal atrial fibrillation prior to procedure Up to 270 minutes
Secondary Electrophysiology Parameters size of left atrium (mm) Up to 270 minutes
Secondary Electrophysiology Parameters left ventricular ejection fraction Up to 270 minutes
Secondary Airway Trauma Any noted trauma in the anesthesia or post-procedure notes, including damage to lips/teeth, laryngospasm, need for reintubation post procedure Up to 7 days
Secondary Post-procedure Nausea Measured by number of doses of antiemetics given in the post-procedure time period mg of Zofran (ondanesteron) given post-operatively Up to 7 days
Secondary Post-procedure Emesis Measured by number of times patient has emesis during post-procedure time period Up to 7 days
Secondary Atrial Fibrillation Recurrence defined as recurrence of paroxysmal atrial fibrillation recurring at any time after 6 weeks past the day of procedure. As standard of care these patients are followed up with Holter monitoring for a period of 6 months. Holter monitoring will be done for 48 hour time periods immediately post-procedure, 2 weeks, 6 weeks, 4 months and 6 months post procedure as is standard of care From end of procedure to six month followup holter monitor
Secondary Aspiration Events aspiration events as noted in the anesthesia, PACU and post procedure notes would be documented Up to 7 days
Secondary Patient Satisfaction patients will be given an survey by study personnel prior to discharge from the hospital; survey will be conducted in person by study personnel Up to six months
Secondary Cost Analysis an analysis of cost to patient as well as overall hospital costs will be conducted Up to six months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A